Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Overview
Liquidia Corporation (LQDA) is a United States-based biopharmaceutical company dedicated to transforming therapy development for pulmonary hypertension and other rare cardiopulmonary diseases. Utilizing its proprietary PRINT® Technology, the company engineers precise, uniform drug particles to optimize drug delivery and improve treatment efficacy. This innovative approach addresses critical gaps in current therapeutic options, ensuring products are manufactured under scalable, cGMP-compliant processes.
Core Technology and Business Model
At its core, Liquidia harnesses the power of PRINT® Technology to overcome common challenges in drug delivery. By producing highly controlled and uniform particles, the company enhances deposition in the lungs, which is vital for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia’s model includes both the advancement of its own pipeline and strategic licensing of its technology to globally recognized pharmaceutical partners.
Product Portfolio and Clinical Focus
Liquidia’s primary product candidate, YUTREPIA™ (treprostinil) inhalation powder, exemplifies its application of precision particle engineering for the treatment of PAH and PH-ILD. The company is also developing additional candidates and formulations, including a sustained-release liposomal version designed for twice-daily administration, further diversifying its clinical offerings. This broad clinical focus reinforces Liquidia’s commitment to addressing unmet patient needs.
Market Position and Competitive Landscape
Positioned in a competitive biopharmaceutical landscape, Liquidia distinguishes itself through its unique technological platform and rigorous adherence to quality standards. Its scalable PRINT® process, combined with robust clinical research and strategic partnerships, offers a scientifically sound alternative in a market with significant unmet needs. Industry-specific terms such as "drug particle engineering", "inhaled therapeutics", and "cGMP compliance" attest to the company’s technical expertise and operational rigor.
Operational Excellence and Regulatory Focus
Liquidia’s operations are streamlined across its specialized subsidiaries, ensuring efficient research, development, and commercialization processes. The company maintains a strict focus on quality by aligning its manufacturing practices with the highest regulatory standards, hence building a foundation of trust and reliability in its product offerings. This diligence in quality control and regulatory adherence solidifies its reputation within the oncology and pulmonary care communities.
Industry Collaboration and Strategic Partnerships
Liquidia actively collaborates with major pharmaceutical entities, both to license its PRINT® platform and to accelerate the commercialization of its products. These partnerships allow for a mutual exchange of expertise and resources, further enhancing its market reach and ensuring that advanced therapies are delivered efficiently. Such strategic alliances are critical for fostering innovation and establishing a competitive advantage in the complex healthcare landscape.
Commitment to Innovation and Quality
With a commitment to continuous innovation, Liquidia leverages extensive clinical studies and state-of-the-art manufacturing processes to bring safer and more effective treatment options to patients. Emphasizing precision in every phase of development, the company sets itself apart by ensuring that its therapies are optimally designed to tackle the challenges of pulmonary hypertension and related ailments.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will deliver a fireside chat presentation on Wednesday, April 9, 2025, at 8:45 a.m. ET.
Investors and interested parties can access the live webcast through the 'Investors' section of Liquidia's website. A recorded version of the presentation will remain available on the company's website for a minimum of 30 days after the event.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will deliver a fireside chat presentation on Tuesday, April 8, 2025, at 8:45 a.m. ET.
Investors and interested parties can access the live webcast through the 'Investors' section of Liquidia's website. A recorded version of the presentation will remain available for a minimum of 30 days after the event on the company's website.
Liquidia (NASDAQ: LQDA) announced the FDA's acceptance of its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder. The treatment targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The FDA classified the resubmission as a complete, Class 1 response to the previous action letter from August 16, 2024, which had granted tentative approval for both indications. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025.
Liquidia (NASDAQ: LQDA) has announced three poster presentations at the upcoming American Thoracic Society (ATS) 2025 International Conference in San Francisco, scheduled for May 18-21, 2025.
Two posters will present new data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients, focusing on safety, tolerability, and exploratory changes in 6-minute walk distance, quality of life, and cardiac effort. The third poster features a case study from the INSPIRE study, examining long-term safety and tolerability in a PAH patient transitioning from parenteral treprostinil.
The presentations are scheduled for Tuesday, May 20, 2025, from 11:30 a.m. to 1:15 p.m. PT, with Dr. Rajan Saggar, Dr. Daniel Lachant, and Dr. Rodolfo Estrada as presenting authors. All posters will be available on Liquidia's website after the presentations.
Liquidia (NASDAQ: LQDA) reported its full year 2024 financial results, highlighting key developments and financial performance. The company is awaiting final FDA approval for YUTREPIA™ after regulatory exclusivity expires on May 23, 2025, following its tentative approval for PAH and PH-ILD treatment in August 2024.
Financial highlights include:
- Cash position of $176.5 million as of December 31, 2024
- Revenue decreased to $14.0 million from $17.5 million in 2023
- Net loss widened to $130.4 million ($1.66 per share) from $78.5 million in 2023
The company strengthened its financial position through an amended agreement with HealthCare Royalty Partners, providing access to up to $100 million in additional financing. The ASCENT study evaluating YUTREPIA in PH-ILD patients is nearing completion, while development of L606, a twice-daily liposomal treprostinil formulation, continues to progress.
Liquidia (NASDAQ: LQDA) has amended its agreement with HealthCare Royalty (HCRx) to secure up to $100 million in additional financing through three tranches:
- $25 million available at closing
- $50 million upon first commercial sale of YUTREPIA™ after FDA approval for PAH and PH-ILD treatment
- $25 million upon reaching $100 million in YUTREPIA sales by June 30, 2026
The funds will support YUTREPIA's commercial development, clinical trials including pediatric studies, L606 development, and general corporate purposes. The agreement includes fixed payment schedules until 2032, with payments capped at 175% of advanced amounts, plus potential true-up payments based on minimum return rates of 16%, 13%, and 12% for the three tranches.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease therapies, has scheduled the release of its full year 2024 financial results for March 19, 2025. The company will conduct a live webcast at 8:30 a.m. Eastern Time to present the financial results and provide a corporate update. Investors can access the webcast through Liquidia's website, where it will remain archived for one year.
Liquidia (NASDAQ: LQDA) has announced that its CEO, Dr. Roger Jeffs, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.
The event will feature a live, audio-only webcast accessible via the “Investors” page on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. For those unable to attend live, a replay and transcript of the webcast will be archived on the company's website for at least 30 days.
Liquidia (NASDAQ: LQDA) reported Q3 2024 financial results, highlighting key developments including FDA tentative approval for YUTREPIA™ for PAH and PH-ILD treatments. Revenue increased to $4.4M from $3.7M year-over-year. The company strengthened its balance sheet by raising approximately $100M through equity offering and financing agreement. Net loss widened to $23.2M ($0.30 per share) compared to $15.8M ($0.24 per share) in Q3 2023. Cash position improved to $204.4M as of September 30, 2024. Launch of YUTREPIA is currently gated until May 23, 2025, due to TYVASO DPI's exclusivity period.
Liquidia (NASDAQ: LQDA), a biopharmaceutical company focused on rare cardiopulmonary disease treatments, has announced its upcoming presentation at the Stifel 2024 Healthcare Conference in New York City. The presentation is scheduled for Tuesday, November 19, 2024, from 3:00 to 3:30 p.m. ET.
Investors and interested parties can access the live webcast through Liquidia's website investor section. A recorded version will remain available on the company's website for at least 30 days after the event.